Position in COGT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$24,690,367
-$5,315,282 QoQ
Shares Held
637,994
-18.2% QoQ
Ownership
0.368%
of shares outstanding
% of Portfolio
0.94%
of 13F equity value
Holder Rank
#56
of 321 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in COGT Over Time
Shares Held
Position Value (USD)
Derivatives in COGT
reported options exposure · as of Mar 31, 2026CallValue
$2,601,924
CallShares
67,600
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026J. Goldman & Co LP holds $154,729,761 across 52 Biotechnology names. COGT ranks #1 (16.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
This page
|
637,994 | $24,690,367 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
38,698 | $11,649,258 | |
| 3 | CAPR |
Capricor Therapeutics, Inc.
|
427,321 | $10,289,889 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
601,972 | $8,132,641 | |
| 5 | ARDX |
Ardelyx, Inc.
|
1,579,828 | $8,057,122 | |
| 6 | URGN |
UroGen Pharma Ltd.
|
212,775 | $7,830,120 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,311 | $6,115,243 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
112,129 | $5,690,546 |
All Filings in COGT
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $24,690,367 | 637,994 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,601,924 | 67,600 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $30,005,649 | 779,570 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $15,602,834 | 439,269 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||